Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

Next Previous
Trial Profile

A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erdafitinib (Primary) ; Docetaxel; Pembrolizumab; Vinflunine
  • Indications Carcinoma; Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms THOR
  • Sponsors Janssen; Janssen Research & Development; Janssen-Cilag

    • Most Recent Events

    • 03 Apr 2019 Planned End Date changed from 1 Feb 2021 to 5 Nov 2021.
    • 14 Nov 2018 Planned End Date changed from 30 Apr 2022 to 1 Feb 2021.
    • 01 May 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top